Answers are grounded in this paper and cite their sources.
In 2003, the Centers for Medicare and Medicaid Services (CMS) made an increase in arteriovenous fistula (AVF) prevalence and a decrease in catheter prevalence a priority, initiating a project known since 2005 as the Fistula First Breakthrough Initiative (FFBI). From 2003 to June 2010, the prevalent AVF in use rate has increased from 32.2% to 55.8% according to CMS data, a remarkable achievement yet short of CMS's 66% prevalent AVF goal. The prevalent catheter rate decreased from 26.9% to 23.8% during this same period. Although an effort to augment AVF placement has resulted in issues of nonmaturation, the primary contributor to the 23.8% prevalent catheter rate is the 82% incident catheter rate, which has not declined significantly. Future efforts to decrease the prevalent catheter rate and increase the prevalent AVF rate must be directed at patients with stages 4 and 5 chronic kidney disease and the healthcare providers and practitioners involved in their care, including hospital systems, surgeons, referring physicians, and nephrologists. The nephrologist plays a key role in providing guidance to those providers and holding them accountable for improved vascular access outcomes.
No takes yet. Share an insight, caveat, or question.
Jay B. Wish (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: